Open AccessJournal Article
Marine natural products as anticancer drugs
TLDR
This review highlights several marine natural products and their synthetic derivatives that are currently undergoing clinical evaluation as anticancer drugs.Abstract:
The chemical and biological diversity of the marine environment is immeasurable and therefore is an extraordinary resource for the discovery of new anticancer drugs. Recent technological and methodologic advances in structure elucidation, organic synthesis, and biological assay have resulted in the isolation and clinical evaluation of various novel anticancer agents. These compounds range in structural class from simple linear peptides, such as dolastatin 10, to complex macrocyclic polyethers, such as halichondrin B; equally as diverse are the molecular modes of action by which these molecules impart their biological activity. This review highlights several marine natural products and their synthetic derivatives that are currently undergoing clinical evaluation as anticancer drugs.read more
Citations
More filters
Journal ArticleDOI
Marine natural products.
TL;DR: This review covers the literature published in 2014 for marine natural products, with 1116 citations referring to compounds isolated from marine microorganisms and phytoplankton, green, brown and red algae, sponges, cnidarians, bryozoans, molluscs, tunicates, echinoderms, mangroves and other intertidal plants and microorganisms.
Journal ArticleDOI
Sponge-Associated Microorganisms: Evolution, Ecology, and Biotechnological Potential
TL;DR: The ecology of sponge-microbe associations is examined, including the establishment and maintenance of these sometimes intimate partnerships, the varied nature of the interactions (ranging from mutualism to host-pathogen relationships), and the broad-scale patterns of symbiont distribution.
Journal ArticleDOI
Natural compounds for cancer treatment and prevention
Stefania Nobili,Donatella Lippi,Ewa Witort,Martino Donnini,L Bausi,Enrico Mini,Sergio Capaccioli +6 more
TL;DR: The main natural compounds used in cancer therapy and prevention, the historical aspects of their application and pharmacognosy, and some critical aspects of current cancer chemotherapy are discussed, focusing on genetics and genomics.
Journal ArticleDOI
Natural products as leads to anticancer drugs.
TL;DR: Semisynthesis processes of new compounds, obtained by molecular modification of the functional groups of lead compounds, are able to generate structural analogues with greater pharmacological activity and with fewer side effects.
Journal ArticleDOI
Patellamide A and C biosynthesis by a microcin-like pathway in Prochloron didemni, the cyanobacterial symbiont of Lissoclinum patella.
Eric W. Schmidt,James T. Nelson,David A. Rasko,Sebastian Sudek,Jonathan A. Eisen,Margo G. Haygood,Jacques Ravel +6 more
TL;DR: The full sequencing and functional expression of a marine natural-product pathway from an obligate symbiont is presented, and a related cluster was identified in Trichodesmium erythraeum IMS101, an important bloom-forming cyanobacterium.
References
More filters
Journal ArticleDOI
Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.
Motohiro Kobayashi,Tsugitaka Natsume,Satoru Tamaoki,Junichi Watanabe,Hajime Asano,Takashi Mikami,Katsuhiko Miyasaka,Koichi Miyazaki,Masaaki Gondo,Kyoichi Sakakibara,Shigeru Tsukagoshi +10 more
TL;DR: TZT‐1027 was also effective against human xenografts, that is, tumor regression was observed in mice bearing MX‐1 breast and LX‐1 lμng carcinomas, and has been entered into phase I clinical trials.
Journal ArticleDOI
Approaches to identify, clone, and express symbiont bioactive metabolite genes.
Mark Hildebrand,Laura E. Waggoner,Laura E. Waggoner,Grace E. Lim,Katherine H. Sharp,Christian P. Ridley,Margo G. Haygood +6 more
TL;DR: This review discusses approaches to identify, clone, and express bioactive metabolite genes from symbionts of marine invertebrates, using the Bugula neritina/Endobugula sertula association as a primary example.
Journal Article
Phase I Trial of Dolastatin-10 (NSC 376128) in Patients with Advanced Solid Tumors
Henry C. Pitot,Edwin A. McElroy,Joel M. Reid,Anthony J. Windebank,Jeff A. Sloan,Charles Erlichman,Pamela G. Bagniewski,Denise L. Walker,Joseph Rubin,Richard M. Goldberg,Alex A. Adjei,Matthew M. Ames +11 more
TL;DR: In conclusion, dola-10 administered every 3 weeks as a peripheral i.v. bolus is well tolerated with dose-limiting toxicity of granulocytopenia, and the maximum tolerated dose (and recommended Phase II starting dose) is 400 microg/m2 for patients with minimal prior treatment (two or fewer prior chemotherapy regimens).
Journal ArticleDOI
Synthetic studies on the marine natural product halichondrins
Hyeong-Wook Choi,Damtew Demeke,Fu-An Kang,Yoshito Kishi,Katsumasa Nakajima,Pawel Nowak,Zhao-Kui Wan,Chaoyu Xie +7 more
TL;DR: In this paper, the right half and its analog E7389 of halichondrin B were synthesized via a regiospecific and stereoselective S N 2' process using stable and crystalline Cr(III)/sulfonamide complexes.
Journal ArticleDOI
The discovery of NVP-LAQ824: from concept to clinic.
TL;DR: A systematic structural exploration of cinnamyl hydroxamates based on NVP-LAK974 was undertaken with the goal of finding a novel, well-tolerated and efficacious HDAC inhibitor, and several derivatives were found to be efficacious in the xenograft assay.